• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.

    5/15/25 4:15:23 PM ET
    $TARS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TARS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Tarsus Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    87650L103

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    87650L103


    1Names of Reporting Persons

    TANG CAPITAL MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,454,797.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,454,797.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,454,797.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.90 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Tang Capital Management, LLC ("TCM") shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc. ("TCP III"), Tang Capital Partners IV, Inc. ("TCP IV") and Kevin Tang. The percentages used herein are based on 41,580,162 shares of Common Stock outstanding as of February 29, 2025, as set forth in the Issuer's Prospectus filed on Form 424B5 that was filed with the Securities and Exchange Commission on March 13, 2025.


    SCHEDULE 13G

    CUSIP No.
    87650L103


    1Names of Reporting Persons

    KEVIN TANG
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,454,797.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,454,797.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,454,797.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.90 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III, TCP IV and TCM.


    SCHEDULE 13G

    CUSIP No.
    87650L103


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,334,439.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,334,439.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,334,439.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.61 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  TCP shares voting and dispositive power over such shares with TCM and Kevin Tang.


    SCHEDULE 13G

    CUSIP No.
    87650L103


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS INTERNATIONAL, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    62,358.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    62,358.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    62,358.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.15 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang.


    SCHEDULE 13G

    CUSIP No.
    87650L103


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS III, INC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    43,500.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    43,500.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    43,500.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.10 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang.


    SCHEDULE 13G

    CUSIP No.
    87650L103


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS IV, INC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    14,500.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    14,500.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    14,500.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.04 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  TCP IV shares voting and dispositive power over such shares with TCM and Kevin Tang.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Tarsus Pharmaceuticals, Inc.
    (b)Address of issuer's principal executive offices:

    15440 Laguna Canyon Road, Suite 160, Irvine, CA, 92618
    Item 2. 
    (a)Name of person filing:

    This Statement on Schedule 13G (this "Statement") is filed by TCM, the general partner of TCP and TCPI; Kevin Tang, the manager of TCM and Chief Executive Officer of TCP III and TCP IV; TCP; TCPI; TCP III; and TCP IV.
    (b)Address or principal business office or, if none, residence:

    The address of TCM, Kevin Tang, TCP and TCPI is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.
    (c)Citizenship:

    TCM is a Delaware limited liability company. Mr. Tang is a United States citizen. TCP and TCPI are Delaware limited partnerships. TCP III and TCP IV are Nevada corporations that are indirectly wholly owned by TCP.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    87650L103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,454,797
    (b)Percent of class:

    5.90%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0 shares

     (ii) Shared power to vote or to direct the vote:

    2,454,797 shares

     (iii) Sole power to dispose or to direct the disposition of:

    0 shares

     (iv) Shared power to dispose or to direct the disposition of:

    2,454,797 shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    TANG CAPITAL MANAGEMENT, LLC
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager
    Date:05/15/2025
     
    KEVIN TANG
     
    Signature:/s/ Kevin Tang
    Name/Title:Self
    Date:05/15/2025
     
    TANG CAPITAL PARTNERS, LP
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager, Tang Capital Management, LLC, General Partner
    Date:05/15/2025
     
    TANG CAPITAL PARTNERS INTERNATIONAL, LP
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager, Tang Capital Management, LLC, General Partner
    Date:05/15/2025
     
    TANG CAPITAL PARTNERS III, INC
     
    Signature:/s/ Kevin Tang
    Name/Title:Chief Executive Officer
    Date:05/15/2025
     
    TANG CAPITAL PARTNERS IV, INC
     
    Signature:/s/ Kevin Tang
    Name/Title:Chief Executive Officer
    Date:05/15/2025
    Get the next $TARS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TARS

    DatePrice TargetRatingAnalyst
    6/2/2025$75.00Outperform
    Oppenheimer
    5/27/2025$72.00Buy
    H.C. Wainwright
    11/20/2023$19.00Neutral
    Goldman
    7/18/2023$44.00Outperform
    William Blair
    5/18/2023Buy
    Guggenheim
    8/1/2022$40.00Overweight
    Barclays
    12/21/2021$40.00Buy
    HC Wainwright & Co.
    11/23/2021$55.00Outperform
    Oppenheimer
    More analyst ratings

    $TARS
    SEC Filings

    See more
    • SEC Form 144 filed by Tarsus Pharmaceuticals Inc.

      144 - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      6/9/25 10:21:06 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.

      SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      5/15/25 4:15:23 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Tarsus Pharmaceuticals Inc.

      SCHEDULE 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      5/7/25 11:27:44 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tarsus Pharmaceuticals Inc.

      SC 13G - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 4:41:12 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

      SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 4:35:55 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tarsus Pharmaceuticals Inc.

      SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)

      11/14/24 3:05:35 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Financials

    Live finance-specific insights

    See more
    • Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements

      Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position with approximately $135 million raised in public equity offering; cash, cash equivalents and marketable securities of approximately $408 million as of March 31, 2025 On-track to initiate a Phase 2 trial of TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea in H2 2025 Management to host conference call today, May 1, 2025, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announce

      5/1/25 4:05:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

      IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to ad

      4/24/25 5:00:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements

      Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of launch Presented groundbreaking XDEMVY data; first pharmacologic treatment to demonstrate functional improvements in Meibomian Gland Disease and patient symptoms in Demodex blepharitis patients Continued advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, the next category-creating opportunity in eye care Management to host conference call today, February 25, 2025, at 5 a.m. PT / 8 a.m. ET IRVINE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced

      2/25/25 7:00:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Leadership Updates

    Live Leadership Updates

    See more
    • Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors

      Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Katherine H. (Kate) Goodrich, M.D., MHS, Chief Medical Officer of Humana Inc., to its Board of Directors. Dr. Goodrich is a seasoned executive and practicing physician who has dedicated her career to championing innovative healthcare initiatives designed to improve healthcare access

      11/13/24 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer

      IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus' Chief Medical Advisor since 2020 and as a Board member since 2021. In this new role, she will be responsible for leading the strategy, direction and execution of the Company's new Medical Organization compris

      11/5/24 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

      IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Mr. Farrow succeeds Leo Greenstein who served as CFO since 2020 and will be leaving Tarsus to pursue other professional interests. Mr. Farrow is a seasoned finance and corporate strategy executive with more than two decades of experience successfully leading teams in the life science industry, including several publicly tra

      4/24/23 8:30:00 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer resumed coverage on Tarsus Pharmaceuticals with a new price target

      Oppenheimer resumed coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $75.00

      6/2/25 8:55:36 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright resumed coverage on Tarsus Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of Tarsus Pharmaceuticals with a rating of Buy and set a new price target of $72.00

      5/27/25 9:11:10 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Tarsus Pharmaceuticals with a new price target

      Goldman initiated coverage of Tarsus Pharmaceuticals with a rating of Neutral and set a new price target of $19.00

      11/20/23 7:55:38 AM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for XDEMVY issued to TARSUS PHARMACEUTICALS, INC.

      Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:35:13 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for issued to TARSUS PHARMACEUTICALS, INC.

      Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:35:13 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • FDA Approval for issued to TARSUS PHARMACEUTICALS, INC

      Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity

      7/25/23 4:29:16 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Mottiwala Aziz sold $765,800 worth of shares (17,500 units at $43.76), decreasing direct ownership by 27% to 47,557 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      6/11/25 4:50:49 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • President/CEO and Board Chair Azamian Bobak R. sold $300,000 worth of shares (6,000 units at $50.00) (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/26/25 4:47:19 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Commercial Officer Mottiwala Aziz sold $505,856 worth of shares (10,565 units at $47.88), decreasing direct ownership by 14% to 65,057 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      3/20/25 9:49:54 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Goldberg Andrew D. bought $18,960 worth of shares (1,000 units at $18.96), increasing direct ownership by 50% to 3,000 units (SEC Form 4)

      4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)

      12/19/23 6:30:59 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TARS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tarsus to Participate in Upcoming Investor Conferences

      IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 6:00 a.m. PT / 8:00 a.m. CTJefferies Global Healthcare Conference on Wednesday, June 4th, at 12:45 p.m. PT / 3:45 p.m. ETGoldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th, at 10:20 a.m. PT / 1:20 p.m. ET Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limit

      5/29/25 5:00:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tarsus to Participate in Upcoming Investor Conferences

      IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) today announced that management plans to participate in the following upcoming investor conferences: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13th, at 3:40 p.m. PT / 6:40 p.m. ETH.C. Wainwright & Co. 3rd Annual BioConnect Nasdaq Investor Conference on Tuesday, May 20th, at 12:00 p.m. PT / 3:00 p.m. ETStifel Virtual Ophthalmology Forum on Tuesday, May 27th, at 7:30 a.m. PT / 10:30 a.m. ET Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours a

      5/8/25 5:00:00 PM ET
      $TARS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

      GREENFIELD, Ind., May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash. Monetization of this non-core asset will be used to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025. Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce inte

      5/5/25 6:27:00 AM ET
      $ELAN
      $TARS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)